Mass balance study of [<sup>14</sup>C]SHR0302, a selective and potent JAK1 inhibitor in humans-Reference-Cited by-同舟云学术

Mass balance study of [¹⁴C]SHR0302, a selective and potent JAK1 inhibitor in humans

Published:2023-02-01 Issue:2 Volume:53 Page:69-83
ISSN:0049-8254
Container-title:Xenobiotica
language:en
Short-container-title:Xenobiotica

Author:

Ge Xinyu¹²,Ma Sheng³⁴,Yan Shu²,Wu Yali²,Chen Chong¹²,Tang Chongzhuang²,Zhan Yan²,Bian Yi-cong³⁴,Shen Kai⁵,Feng Sheng⁵,Gao Xuehu⁵,Zhong Dafang²,Zhang Hua³⁴,Miao Li-yan³⁴⁶⁷,Diao Xing-xing¹²

Affiliation:

1. School of Chinese Materia Medica, Nanjing University of Chinese Medicine, Nanjing, China

2. Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China

3. Department of Pharmacy, the First Affiliated Hospital of Soochow University, Suzhou, China

4. Institute for Interdisciplinary Drug Research and Translational Sciences, Soochow University, Suzhou, China

5. Jiangsu Hengrui Medicine Co., Ltd, Lianyungang, China

6. College of Pharmaceutical Sciences, Soochow University, Suzhou, China

7. National Clinical Research Center for Hematologic Diseases, The First Affiliated Hospital of Soochow University, Jiangsu, China

Funder

National Natural Science Foundation of China

National Key New Drug Creation Special Programs

Key R&D Program of Jiangsu Province

Suzhou Health Leading Talent

the National Clinical Research Center for Hematologic Diseases

the Priority Academic Program Development of the Jiangsu Higher Education Institutes

Publisher

Informa UK Limited

Subject

Health, Toxicology and Mutagenesis,Pharmacology,Toxicology,Biochemistry,General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/00498254.2023.2176267

Reference51 articles.

1. Are Young Women and Men with Rheumatoid Arthritis at Risk for Fragility Fractures? A Population-based Study

2. Quantities used in radiological protection

3. Early phase studies of JAK1 selective inhibitors in rheumatoid arthritis

4. A pharmacokinetic and clinical assessment of tofacitinib for the treatment of rheumatoid arthritis

5. Therapeutic targeting of JAKs: from hematology to rheumatology and from the first to the second generation of JAK inhibitors

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Pharmacokinetics, mass balance, and metabolism of [14C]PLB1004, a selective and irreversible EGFR-TKI in humans;2024-09-06

2. Metabolite characterisation of the peptide–drug conjugate LN005 in liver S9s by UHPLC-Orbitrap-HRMS;Xenobiotica;2023-12-04

3. Identification of Selective JAK3/STAT1 and CYP34A from Pyrazolopyrimidine Derivatives: A Search for Potential Drug Targets for Rheumatoid Arthritis using In-silico Drug Discovery Techniques;Letters in Drug Design & Discovery;2023-08-21

4. Effect of CYP3A4 induction and inhibition on the pharmacokinetics of SHR0302 in healthy subjects;British Journal of Clinical Pharmacology;2023-04-17